OncoSil Medical Ltd

Receive alerts
Market Cap:
$39.73 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-25 of 87


OncoSil Medical attracts $16.7 million for breakthrough pancreatic cancer radiation treatment

OncoSil is a first in class medical device for the treatment of unresectable locally advanced pancreatic cancer....

on 19/4/18

OncoSil Medical seen as undervalued by broker following success with pancreatic cancer treatment trials

The global target market for pancreatic and liver cancer is estimated to be about US$3.5 billion. ...

on 11/4/18

OncoSil Medical reveals positive data from pancreatic cancer clinical study

100% disease control rate achieved by the company's device at week 8....

on 23/10/17

OncoSil Medical gets ready to present pancreatic cancer clinical study data

More concentrated and localised beta radiation compared to external beam radiation....

on 16/10/17

OncoSil Medical continues to advance its pancreatic cancer study

10 subjects in the study group have now been successfully implanted with the device....

on 22/9/17

OncoSil Medical achieves steady progress in pancreatic cancer study

A CE Mark application to commercially sell OncoSil™ in Europe is under review....

on 22/8/17

OncoSil Medical wins key approval

OncoSil is focused on treatments for pancreatic and liver cancer....

on 19/4/17

Oncosil Medical attracts broker attention

Oncosil has enrolled the first patient in the OncoPac-1 trial....

on 4/4/17

OncoSil Medical crosses a milestone in global pancreatic cancer study

Recruited the first subject for a global study of OncoSil™ device....

on 28/3/17

OncoSil Medical outlines timeline for CE Mark

OncoSil is well positioned to collect the supplemental data quickly....

on 9/2/17

OncoSil Medical Ltd updates on Pancreatic Cancer Clinical Study

Daniel Kenny, chief executive officer, commented: "I am are delighted with the participation of these four prestigious centres in our global clinical program."...

on 28/11/16

OncoSil Medical Ltd: Broker boosts price target

OncoSil Medical Ltd has been receiving a lot of broker attention recently....

on 9/11/16

OncoSil Medical Ltd's well-funded and delivering milestones

OncoSil Medical Ltd (ASX:OSL) ended the September quarter with $13.8 million in cash, and during the period delivered milestones....

on 28/10/16

OncoSil Medical Ltd receives a Buy recommendation

OncoSil has received a Buy rating and $0.42 per share price target from Wilsons Research....

on 19/10/16

OncoSil Medical Ltd swells cash position after tax refund

OncoSil is a clinical-stage medical device company seeking to provide a new medical radiation treatment for cancer subjects....

on 26/9/16

OncoSil Medical Ltd completes key step towards commercial sales

The manufacturing, supply chain validation and delivery to clinical and commercial centres of the OncoSil product is a key step to commercial sales and the treatment of patients in the OncoPac-1 study....

on 18/8/16

OncoSil Medical Ltd shines under broker spotlight

OncoSil has been receiving some strong broker attention recently, as the company moves closer to commercial revenue....

on 16/8/16

Oncosil Medical Ltd: Commercial Revenues Closer

Bell Potter noted: "The awarding of the IDE is a major step forward for this first in class therapy, consequently the valuation is raised by 10% to $0.33."...

on 12/8/16

OncoSil Medical Ltd: IDE Approval from the U.S. Food and Drug Administration

Daniel Kenny, CEO, commented: “We are delighted to receive FDA approval for the IDE which is a significant milestone in our regulatory pathway and a validation of our product and supporting processes to commence this important clinical study."...

on 2/8/16

OncoSil Medical Ltd confident of a successful outcome with the FDA

OncoSil has continued to make progress with its two key regulatory filings during the June quarter 2016, which remain the primary focus and value enablers for the OncoSil™ technology....

on 28/7/16

OncoSil Medical Ltd remains confident on CE Mark and IDE submissions

Daniel Kenny, CEO, commented: "We are delighted with the progress we have been making to prosecute and progress both our CE mark and IDE submissions."...

on 30/6/16

OncoSil Medical Ltd: Thoughts on OncoSil's regulatory situation

WilsonHTM noted: "If the FDA allows Oncosil’s IDE study in the coming months, then that should correspond to more regular positive new flow over the balance of 2016."...

on 17/6/16

OncoSil Medical Ltd confident CE Mark will be granted in near-term

Daniel Kenny, CEO, said: "Our key focus in the shorter term is to achieve the CE Mark and enable commercial launch and first sales. We remain optimistic about a favourable decision shortly on the CE Mark."...

on 29/4/16